12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GSK961081: Phase IIb started

GlaxoSmithKline began a double-blind, double-dummy, placebo-controlled, international Phase IIb trial in about 425 patients to evaluate once-daily 100, 400 or 800 µg doses or twice-daily 100, 200 or 400 µg doses of...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >